VALENCIA - Diabetics with an aversion to needles can avoid the painful experience of injecting insulin altogether thanks to Afrezza, the first inhaled insulin drug on the market approved by the Food and Drug Administration and produced by MannKind Corp., a biopharmaceutical company based in Southern California.
MannKind, which also operates a plant in Connecticut, specializes in pulmonary drug delivery system technology, so instead o... (continued)